-
Most Favored Nation (MFN) Is Altering Biopharma Drug Pricing Forever
Written by
Key Takeaways Target Audiences Innovative Biopharma Executives (US)Executives with assets in early stages of development or nearing US FDA approval, as well as those seeking ex-US launch partners. Big Pharma Executives in ex-US AffiliatesExecutives who are part of the OECD19 and simply trying to understand the pressures being faced by their global and US colleagues,
